Mesoblast files applications with US FDA for HLHS therapy
The company has filed the applications based on Revascor’s data from a randomised, blinded, controlled prospective study carried out at a single centre in the US involving 19
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Kyverna Therapeutics’ chimeric antigen receptor (CAR) T-cell product candidate, KYV-101 for treating refractory stiff-person syndrome (SPS).
A therapy platform developed by T3 Pharma using engineered Yersinia enterocolitica bacteria, delivers immune-modulating proteins to cancer cells and tumour micro-environments, sparing healthy tissues. The bacteria can be